Genetic Technologies Ltd ADS - ADR Peer Comparison
$0.77
$-0.01
(-0.65%)
As on 29-Jan-2025 09:30EDT
Market cap
$4 Mln
Revenue (TTM)
$14 Mln
P/E Ratio
--
P/B Ratio
3.3
Div. Yield
0 %
Edit
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
4 | 153 | 85 | 57 | 9 |
Revenue (A$ Mln) |
8 | 0 | 5 | 5 | 7 |
Net Profit (A$ Mln) |
-12.02 | -20.70 | -12.15 | -61.43 | -5.22 |
Net Margin (%) |
-132.59 | -2,284,277.09 | -531.34 | -1,030.32 | -71.92 |
RoE (%) |
-184.98 | 226.03 | -43.23 | -36.88 | -50.30 |
Price to Earnings |
-- | -- | -- | -- | -- |
Price-To-Book |
3.29 | 4.63 | 2.19 | 0.81 | 1.03 |
Income Statement (A$ Mln)
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
7.66 | 2.31 | 4.02 | 3.84 | 4.90 |
|
Cost of Revenue
|
3.76 | -- | 0.21 | 41.55 | 1.57 |
|
Gross Profit
|
3.90 | 2.31 | 3.80 | -37.70 | 3.34 |
|
Operating Expenses
|
16.11 | 30.77 | 23.41 | 50.40 | 9.14 |
|
Operating Profit (EBIT)
|
-12.21 | -28.46 | -19.60 | -88.10 | -5.80 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-12.02 | -27.05 | -19.08 | -42.72 | -6.94 |
|
Provision for Tax
|
-1.99 | -0.27 | 0.05 | 0.00 | -0.76 |
|
Profit after Tax (Net Income)
|
-12.02 | -26.78 | -19.12 | -42.72 | -6.94 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities (A$ Mln)
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1.83 | -10.02 | 13.80 | 189.52 | 12.71 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.16 | 5.81 | 0.05 | 1.57 | 0.14 |
|
Current Liabilities
|
4.20 | 25.80 | 5.37 | 10.49 | 2.70 |
|
Total Liabilities
|
6.19 | 21.59 | 19.22 | 201.58 | 15.55 |
Assets (A$ Mln)
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2.49 | 15.44 | 0.19 | 10.23 | 0.82 |
|
Current Assets
|
3.70 | 6.15 | 19.04 | 191.35 | 14.73 |
|
Total Assets
|
6.19 | 21.59 | 19.22 | 201.58 | 15.55 |
|
Total Debt*
|
0.88 | 0.63 | 0.16 | 1.59 | 0.17 |
|
Net Current Assets
|
-0.50 | -19.65 | 13.66 | 180.86 | 12.03 |
Cashflow (A$ Mln)
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-9.68 | -9.58 | -12.61 | -34.82 | -5.88 |
|
Cash Flow from Investing Activities
|
0.11 | -- | -0.01 | -21.02 | 0.33 |
|
Cash from Financing Activities
|
2.82 | 5.99 | 9.22 | 95.18 | 0.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-166.89 | -1,200.00 | -103.42 | -25.98 | -42.44 |
|
ROE (%)
|
-184.98 | -2,634.33 | -104.47 | -26.21 | -42.92 |
|
ROA (%)
|
-114.22 | -107.83 | -82.18 | -24.48 | -36.96 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-156.78 | -1,160.23 | -475.79 | -1,111.87 | -141.49 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.26 | 4,157.56 | 0.03 | 0.10 | 1.72 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-2.27 | -30.85 | -38.51 | -7.07 | -83.20 |
|
EPS Growth (%)
|
0.34 | -643.78 | 0.46 | 0.21 | -0.83 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.62 | 0.00 | -1.00 | -5.72 | -1.99 |
|
Price / Book Value
|
4.07 | -0.01 | 1.38 | 1.29 | 1.08 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.64 | 0.03 | -0.33 | -1.44 | -0.45 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.48 | -0.06 | 0.01 | 0.01 | 0.01 |
|
Short term debt to equity ratio
|
0.47 | -0.06 | 0.01 | 0.00 | 0.00 |
|
Current Ratio
|
0.88 | 0.24 | 3.54 | 18.25 | 5.46 |
|
Quick Ratio
|
0.83 | -- | 3.55 | 18.07 | 4.87 |
|
Interest Coverage
|
-231.79 | -- | -- | -1,521.78 | -688.47 |
Operating Efficiency Ratios
| Genetic Technologies Ltd ADS - ADR | Kazia Therapeutics - ADR | Alterity Therapeutics - ADR | Immutep - ADR | Immuron - ADR (IMRN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
27.74 | 5.76 | 100.56 | 196.74 | 28.30 |
|
Asset Turnover
|
0.73 | 0.09 | 0.17 | 0.02 | 0.26 |
|
Receivable days
|
55.24 | 18.83 | 576.62 | 738.30 | 67.23 |
|
Inventory Days
|
25.85 | -- | 2,170.61 | 8.37 | 282.74 |
|
Payable days
|
111.52 | -- | 1,957.68 | 40.61 | 167.90 |
|
Cash Conversion Cycle
|
-30.42 | -- | 789.55 | 706.07 | 182.08 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
